Does the media prefer PTCT or COAG?

In the previous week, Hemab Therapeutics had 3 more articles in the media than PTC Therapeutics. MarketBeat recorded 12 mentions for Hemab Therapeutics and 9 mentions for PTC Therapeutics. Hemab Therapeutics' average media sentiment score of 0.40 beat PTC Therapeutics' score of 0.34 indicating that Hemab Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hemab Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LNTH or COAG?

In the previous week, Hemab Therapeutics had 5 more articles in the media than Lantheus. MarketBeat recorded 12 mentions for Hemab Therapeutics and 7 mentions for Lantheus. Lantheus' average media sentiment score of 0.71 beat Hemab Therapeutics' score of 0.40 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, COAG or SRRK?

Scholar Rock is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A -$23.98 N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is COAG or SRRK more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Scholar Rock N/A -163.52% -96.67%

Does the media refer more to COAG or SRRK?

In the previous week, Hemab Therapeutics had 7 more articles in the media than Scholar Rock. MarketBeat recorded 12 mentions for Hemab Therapeutics and 5 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.46 beat Hemab Therapeutics' score of 0.40 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is COAG or XENE more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Xenon Pharmaceuticals N/A -49.23% -46.42%

Does the media refer more to COAG or XENE?

In the previous week, Hemab Therapeutics had 6 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 12 mentions for Hemab Therapeutics and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Hemab Therapeutics' score of 0.40 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, COGT or COAG?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Hemab Therapeutics N/A N/A N/A -$23.98 N/A

Is COGT or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Hemab Therapeutics N/A N/A N/A

Does the media favor COGT or COAG?

In the previous week, Hemab Therapeutics had 10 more articles in the media than Cogent Biosciences. MarketBeat recorded 12 mentions for Hemab Therapeutics and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.45 beat Hemab Therapeutics' score of 0.40 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hemab Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Hemab Therapeutics (COAG) Competitors

$49.39 +0.10 (+0.20%)

As of 07/20/2026 04:00 PM Eastern

Compare

COAG vs. PTCT, LNTH, SRRK, XENE, and COGT

Should you buy Hemab Therapeutics stock or one of its competitors? MarketBeat compares Hemab Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hemab Therapeutics include PTC Therapeutics (PTCT), Lantheus (LNTH), Scholar Rock (SRRK), Xenon Pharmaceuticals (XENE), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.

How does Hemab Therapeutics compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Hemab Therapeutics (NASDAQ:COAG) are both mid-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

PTC Therapeutics has higher revenue and earnings than Hemab Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A

In the previous week, Hemab Therapeutics had 3 more articles in the media than PTC Therapeutics. MarketBeat recorded 12 mentions for Hemab Therapeutics and 9 mentions for PTC Therapeutics. Hemab Therapeutics' average media sentiment score of 0.40 beat PTC Therapeutics' score of 0.34 indicating that Hemab Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hemab Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemab Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Hemab Therapeutics' return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Hemab Therapeutics	N/A	N/A	N/A

PTC Therapeutics presently has a consensus target price of $92.29, indicating a potential upside of 18.30%. Hemab Therapeutics has a consensus target price of $48.00, indicating a potential downside of 2.81%. Given PTC Therapeutics' higher possible upside, research analysts clearly believe PTC Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Hemab Therapeutics beats PTC Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Hemab Therapeutics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Hemab Therapeutics (NASDAQ:COAG) are both mid-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

In the previous week, Hemab Therapeutics had 5 more articles in the media than Lantheus. MarketBeat recorded 12 mentions for Hemab Therapeutics and 7 mentions for Lantheus. Lantheus' average media sentiment score of 0.71 beat Hemab Therapeutics' score of 0.40 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Lantheus shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lantheus has a net margin of 18.05% compared to Hemab Therapeutics' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Hemab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Hemab Therapeutics	N/A	N/A	N/A

Lantheus currently has a consensus price target of $110.43, suggesting a potential upside of 5.77%. Hemab Therapeutics has a consensus price target of $48.00, suggesting a potential downside of 2.81%. Given Lantheus' higher possible upside, research analysts clearly believe Lantheus is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Lantheus has higher revenue and earnings than Hemab Therapeutics. Hemab Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.41	$233.56M	$4.15	25.16
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A

Summary

Lantheus beats Hemab Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Hemab Therapeutics compare to Scholar Rock?

Hemab Therapeutics (NASDAQ:COAG) and Scholar Rock (NASDAQ:SRRK) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Hemab Therapeutics presently has a consensus target price of $48.00, indicating a potential downside of 2.81%. Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 10.54%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Scholar Rock is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

In the previous week, Hemab Therapeutics had 7 more articles in the media than Scholar Rock. MarketBeat recorded 12 mentions for Hemab Therapeutics and 5 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.46 beat Hemab Therapeutics' score of 0.40 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scholar Rock	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Hemab Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Scholar Rock	N/A	-163.52%	-96.67%

Summary

Scholar Rock beats Hemab Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Hemab Therapeutics compare to Xenon Pharmaceuticals?

Hemab Therapeutics (NASDAQ:COAG) and Xenon Pharmaceuticals (NASDAQ:XENE) are both mid-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Hemab Therapeutics' return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Hemab Therapeutics has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A
Xenon Pharmaceuticals	$7.50M	851.21	-$345.91M	-$4.70	N/A

Hemab Therapeutics currently has a consensus price target of $48.00, suggesting a potential downside of 2.81%. Xenon Pharmaceuticals has a consensus price target of $77.20, suggesting a potential upside of 16.90%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Hemab Therapeutics had 6 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 12 mentions for Hemab Therapeutics and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.11 beat Hemab Therapeutics' score of 0.40 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xenon Pharmaceuticals beats Hemab Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Hemab Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Hemab Therapeutics (NASDAQ:COAG) are both mid-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Hemab Therapeutics' return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Hemab Therapeutics	N/A	N/A	N/A

Cogent Biosciences presently has a consensus price target of $45.90, suggesting a potential upside of 19.84%. Hemab Therapeutics has a consensus price target of $48.00, suggesting a potential downside of 2.81%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Cogent Biosciences is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Cogent Biosciences is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A

In the previous week, Hemab Therapeutics had 10 more articles in the media than Cogent Biosciences. MarketBeat recorded 12 mentions for Hemab Therapeutics and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.45 beat Hemab Therapeutics' score of 0.40 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hemab Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cogent Biosciences beats Hemab Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Hemab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COAG vs. The Competition

Export

Metric	Hemab Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$2.31B	$648.44M	$4.39B	$12.28B
Dividend Yield	N/A	N/A	38.14%	9.39%
P/E Ratio	-2.06	N/A	23.54	23.94
Price / Sales	N/A	419.01	135.69	91.94
Price / Cash	N/A	N/A	30.17	47.25
Price / Book	N/A	2.60	12.25	6.14
Net Income	N/A	-$75.73M	$120.21M	$331.74M
7 Day Performance	14.04%	2.03%	-1.84%	-1.81%
1 Month Performance	68.91%	13.11%	-2.11%	-1.44%
1 Year Performance	N/A	-77.70%	9.79%	16.33%

Hemab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COAG Hemab Therapeutics	1.5571 of 5 stars	$49.39 +0.2%	$48.00 -2.8%	N/A	$2.31B	N/A	N/A	72	Gap Up High Trading Volume
PTCT PTC Therapeutics	3.3774 of 5 stars	$84.85 -5.2%	$91.57 +7.9%	+63.8%	$7.04B	$1.73B	N/A	1,410	Analyst Forecast
LNTH Lantheus	2.8423 of 5 stars	$105.64 -0.3%	$108.29 +2.5%	+48.8%	$6.88B	$1.54B	25.46	1,193	Positive News
SRRK Scholar Rock	1.938 of 5 stars	$56.71 -2.1%	$56.00 -1.3%	+24.4%	$6.80B	N/A	N/A	140	News Coverage
XENE Xenon Pharmaceuticals	2.8681 of 5 stars	$68.92 -2.9%	$77.20 +12.0%	+109.1%	$6.66B	$7.50M	N/A	210	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COAG) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hemab Therapeutics (COAG) Competitors

COAG vs. PTCT, LNTH, SRRK, XENE, and COGT

How does Hemab Therapeutics compare to PTC Therapeutics?

Summary

How does Hemab Therapeutics compare to Lantheus?

Summary

How does Hemab Therapeutics compare to Scholar Rock?

Summary

How does Hemab Therapeutics compare to Xenon Pharmaceuticals?

Summary

How does Hemab Therapeutics compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hemab Therapeutics (COAG) Competitors

COAG vs. PTCT, LNTH, SRRK, XENE, and COGT

How does Hemab Therapeutics compare to PTC Therapeutics?

Which has higher earnings & valuation, PTCT or COAG?

Does the media prefer PTCT or COAG?

Is PTCT or COAG more profitable?

Do analysts recommend PTCT or COAG?

Summary

How does Hemab Therapeutics compare to Lantheus?

Does the media prefer LNTH or COAG?

Do institutionals and insiders hold more shares of LNTH or COAG?

Is LNTH or COAG more profitable?

Do analysts recommend LNTH or COAG?

Which has preferable valuation & earnings, LNTH or COAG?

Summary

How does Hemab Therapeutics compare to Scholar Rock?

Do analysts recommend COAG or SRRK?

Which has higher valuation & earnings, COAG or SRRK?

Does the media refer more to COAG or SRRK?

Do institutionals & insiders have more ownership in COAG or SRRK?

Is COAG or SRRK more profitable?

Summary

How does Hemab Therapeutics compare to Xenon Pharmaceuticals?

Is COAG or XENE more profitable?

Which has preferable valuation & earnings, COAG or XENE?

Do analysts prefer COAG or XENE?

Do institutionals & insiders hold more shares of COAG or XENE?

Does the media refer more to COAG or XENE?

Summary

How does Hemab Therapeutics compare to Cogent Biosciences?

Is COGT or COAG more profitable?

Do analysts prefer COGT or COAG?

Which has preferable earnings & valuation, COGT or COAG?

Does the media favor COGT or COAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools